Phase 1 Ovarian Cancer Trial, Recruiting NCT07069335 Sponsor: Boryung Pharmaceutical Co., Ltd Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 1 Ovarian Cancer Trial, Recruiting

NCT07069335
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women between the ages of 19 and 74 at the time of signing up for the study
  • People who are willing to voluntarily sign a consent form agreeing to take part in the study
  • People who have been diagnosed with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer linked to a BRCA gene mutation (confirmed or suspected, inherited or developed over time), and who have been taking a stable dose of olaparib for more than 3 months before the screening stage

Who may not be able to join:

  • People who have had a severe allergic reaction to any ingredient in the study drug, or who have a history of a clinically significant allergic reaction to similar medications
  • People who have a digestive or gastrointestinal condition (such as acid reflux disease, stomach spasms, gastritis, stomach ulcers, or Crohn's disease) or who have had stomach or bowel surgery (other than appendix removal or hernia repair) that could affect how the body absorbs the study drug
  • People who are pregnant, possibly pregnant, or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82 2-708-8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Boryung Pharmaceutical Co., Ltd
Registry
ClinicalTrials.gov
Start date
17 June 2025
Est. completion
15 May 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Pharmacokinetic variable - Cmax; Pharmacokinetic variable - AUCtau

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov